NDC product
Tafinlar
NDC 0078-1154 · Novartis Pharmaceuticals Corporation
Key facts
| Product NDC | 0078-1154 |
|---|---|
| Proprietary name | Tafinlar |
| Nonproprietary name | dabrafenib |
| Substances | DABRAFENIB MESYLATE |
| Dosage form | TABLET, FOR SUSPENSION |
| Route | ORAL |
| Labeler | Novartis Pharmaceuticals Corporation |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA217514 |
| Pharmacologic classes | Breast Cancer Resistance Protein Inhibitors [MoA], Cytochrome P450 2B6 Inducers [MoA], Cytochrome P450 2C19 Inducers [MoA], Cytochrome P450 2C8 Inducers [MoA], Cytochrome P450 2C9 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA] and 6 more |
| Marketing start | Mar 16, 2023 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: